SS-31 Cardiolipin Binding

What cardiolipin is

Cardiolipin is an unusual phospholipid with two phosphate heads and four fatty acid tails, which gives it a cone shape. It sits almost entirely in the inner mitochondrial membrane, where it shapes the cristae and holds the respiratory complexes together.

It also anchors cytochrome c, which carries electrons along the chain. Szeto's 2014 review describes the downside: tight binding partly unfolds cytochrome c and turns it into a peroxidase that oxidizes cardiolipin itself.

Why it matters in Barth syndrome

Barth syndrome is caused by mutations in the TAFAZZIN gene (formerly TAZ), which remodels cardiolipin into its mature form. According to GeneReviews, affected males have a raised monolysocardiolipin-to-cardiolipin ratio, and cardiomyopathy and muscle weakness are typical.

How SS-31 reaches the inner membrane

SS-31 is a four-residue peptide (D-Arg-Dmt-Lys-Phe-NH2) that alternates aromatic residues with positively charged ones. The D-arginine and capped tail protect it from peptidases. In 2004 work from Szeto's lab, these peptides concentrated about 1,000-fold in the inner membrane. Later work from the same group reported that uptake doesn't depend on membrane potential.

The case for cardiolipin binding

In a 2013 rat kidney ischemia study (Birk et al.), a fluorescent SS-31 analog bound cardiolipin with high affinity and blocked cytochrome c's peroxidase activity. A 2014 liposome study found SS-31 bound only membranes containing cardiolipin, at about one peptide per cardiolipin. All of this is cell-free or animal work.

The case for a broader mechanism

A 2020 biophysics study by Mitchell and colleagues found SS-31's membrane affinity tracked overall negative surface charge, and proposed that it works partly by changing surface electrostatics. A 2020 cross-linking study (Chavez et al.) found it also contacts mitochondrial proteins, all known cardiolipin binders. "Binds cardiolipin" is probably a simplification. Energy effects are covered in SS-31 and ATP production.

What human trials show

No human study has measured cardiolipin binding. As of October 2026, elamipretide is a prescription medicine, Forzinity, with FDA accelerated approval (September 19, 2025) for Barth syndrome; the label dose is 40 mg by subcutaneous injection once daily. Approval rested on knee strength in a 12-patient trial that missed its primary endpoints, and a confirmatory trial is required. The Phase 3 MMPOWER-3 trial in mitochondrial myopathy also missed. Our SS-31 overview covers every trial.

Performance use is untested

No trial has tested SS-31 in healthy athletes. Nothing shows the cardiolipin mechanism improves endurance in people without mitochondrial disease. Research-use vials aren't the approved medicine, and an August 2026 FDA warning letter to one seller cited its SS-31 mechanism claims.

What we still don't know

Nobody has shown whether cardiolipin binding, or a broader membrane-surface effect, explains benefit in patients. Forzinity's confirmatory trial should show whether stronger knees mean real clinical benefit.